In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated robust immune response, according to findings of a new study led by HMS researchers at Dana-Farber Cancer Institute.

Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still cancer-free years later in a small

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report.

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the vaccine candidate appeared to be safe and produced a clear immune response in all nine patients at high risk for recurrences of their cancer.

A phase 1 trial of a personalized cancer vaccine for stage III/IV clear cell renal cell carcinoma showed promising results. The vaccine trained patients’ immune systems to target cancer cells, preventing recurrence.

Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell carcinoma (RCC) and can target key driver mutations and induce antitumor immunity, according to a study published online Feb.

After their advanced kidney tumors were surgically removed, nine patients were protected from the cancer returning thanks to an experimental, personalized cancer vaccine, researchers reported Feb. 5.

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to long-lasting T cell expansion and no disease recurrence after 40 months.

A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer three years after the pioneering treatment.

A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report. The "personalized cancer vaccines" (PCVs) used by the nine patients in the trial were targeted to genes specific to their tumors,